Document is current

Article History

Received: 2 September 2024

Accepted: 15 January 2025

First Online: 17 January 2025

Declarations

:

: This study was approved by the Ethics Committee of Kitasato University Hospital (approval no. B23-074, date of approval: 27 September 2023) and conducted in accordance with the Declaration of Helsinki. As this was a retrospective observational study using existing medical information, the need for signed informed consent from the patients was waived by the Kitasato University Hospital Ethics Committee. Patients were informed about the purpose and procedures of the study and were given the option to opt-out.

: Not applicable.

: Hiroyuki Muraoka received honoraria from Eisai, Merck, Otsuka, Meiji Seika, Yoshitomi Pharmaceuticals, Sumitomo Pharma, Viatris, Janssen, Takeda Pharmaceuticals, Lundbeck, Japan, and KYOWA Pharmaceutical Industry. Satoru Oishi has received honoraria from Otsuka, Meiji Seika Pharma, Astellas Pharma, Towa Pharmaceuticals, Yoshitomi Pharmaceutical Industries, Sumitomo Pharma, and Viatris. Taiyo Nishikawa has received an honorarium from Sumitomo Pharma. Ken Inada received personal fees from Daiichi Sankyo, Eisai, Eli Lilly, Janssen, Lundbeck Japan, Meiji Seika Pharma, Mitsubishi Tanabe Pharma, Mochida, MSD, Nipro, Novartis, Otsuka, Pfizer, Shionogi, Sumitomo Pharma, Yoshitomiyakuhin, and Viatris, and he received research grant support from Mochida and Sumitomo Pharma. Other authors declare no conflicts of interest.